Advertisement
Screener

Savara Inc (SVRA) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

Savara Inc Net Income (Loss) Available to Common Stockholders, Basic

Savara Inc (SVRA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$40.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-11

  • Savara Inc net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$40.23M.
  • Savara Inc net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$37.28M.
  • Savara Inc net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$32.24M.
  • Savara Inc net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$29.56M.
  • Savara Inc net income (loss) available to common stockholders, basic for fiscal 2025 was -$118.84M.
  • Savara Inc net income (loss) available to common stockholders, basic for fiscal 2024 was -$95.88M.
  • Savara Inc net income (loss) available to common stockholders, basic for fiscal 2023 was -$54.70M.
  • Savara Inc net income (loss) available to common stockholders, basic for fiscal 2022 was -$38.15M.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 3 month as first filedNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 12 monthNet Income (Loss) Available to Common Stockholders, Basic 181 monthNet Income (Loss) Available to Common Stockholders, Basic 184 monthNet Income (Loss) Available to Common Stockholders, Basic 187 monthNet Income (Loss) Available to Common Stockholders, Basic 190 monthNet Income (Loss) Available to Common Stockholders, Basic 193 monthNet Income (Loss) Available to Common Stockholders, Basic 196 monthNet Income (Loss) Available to Common Stockholders, Basic 199 monthNet Income (Loss) Available to Common Stockholders, Basic 202 monthNet Income (Loss) Available to Common Stockholders, Basic 205 monthNet Income (Loss) Available to Common Stockholders, Basic 208 monthNet Income (Loss) Available to Common Stockholders, Basic 211 monthNet Income (Loss) Available to Common Stockholders, Basic 214 month
2026-06-30-$40.23M
10-Q · filed 2026-08-11
-$77.51M
10-Q · filed 2026-08-11
-$109.75M
derived: sum of 3 quarters · filed 2026-08-11
-$139.31M
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31-$37.28M
10-Q · filed 2026-05-12
-$69.52M
derived: sum of 2 quarters · filed 2026-05-12
-$99.08M
derived: sum of 3 quarters · filed 2026-05-12
-$129.48M
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31-$32.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13
-$61.80M
derived: sum of 2 quarters · filed 2026-03-13
-$92.20M
derived: sum of 3 quarters · filed 2026-08-11
-$118.84M
10-K · filed 2026-03-13
2025-09-30-$29.56M
10-Q · filed 2025-11-12
-$59.96M
derived: sum of 2 quarters · filed 2026-08-11
-$86.60M
10-Q · filed 2025-11-12
-$115.64M
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30-$30.40M
10-Q · filed 2026-08-11
-$57.04M
10-Q · filed 2026-08-11
-$86.08M
derived: sum of 3 quarters · filed 2026-08-11
-$110.33M
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31-$26.64M
10-Q · filed 2026-05-12
-$55.68M
derived: sum of 2 quarters · filed 2026-05-12
-$79.93M
derived: sum of 3 quarters · filed 2026-05-12
-$102.17M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$29.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13
-$53.29M
derived: sum of 2 quarters · filed 2026-03-13
-$75.53M
derived: sum of 3 quarters · filed 2026-03-13
-$95.88M
10-K · filed 2026-03-13
2024-09-30-$24.25M
10-Q · filed 2025-11-12
-$46.49M
derived: sum of 2 quarters · filed 2025-11-12
-$66.84M
10-Q · filed 2025-11-12
-$82.94M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$22.24M
10-Q · filed 2025-08-13
-$42.59M
10-Q · filed 2025-08-13
-$58.69M
derived: sum of 3 quarters · filed 2025-08-13
-$75.29M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$20.35M
10-Q · filed 2025-05-13
-$36.45M
derived: sum of 2 quarters · filed 2025-05-13
-$53.04M
derived: sum of 3 quarters · filed 2025-05-13
-$64.49M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$16.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
-$32.70M
derived: sum of 2 quarters · filed 2025-03-27
-$44.14M
derived: sum of 3 quarters · filed 2025-03-27
-$54.70M
10-K · filed 2025-03-27
2023-09-30-$16.60M
10-Q · filed 2024-11-12
-$28.04M
derived: sum of 2 quarters · filed 2024-11-12
-$38.60M
10-Q · filed 2024-11-12
-$48.90M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$11.44M
10-Q · filed 2024-08-12
-$22.00M
10-Q · filed 2024-08-12
-$32.30M
derived: sum of 3 quarters · filed 2024-08-12
-$42.69M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$10.56M
10-Q · filed 2024-05-09
-$20.86M
derived: sum of 2 quarters · filed 2024-05-09
-$31.24M
derived: sum of 3 quarters · filed 2024-05-09
-$40.41M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$10.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07
-$20.69M
derived: sum of 2 quarters · filed 2024-03-07
-$29.85M
derived: sum of 3 quarters · filed 2024-03-07
-$38.15M
10-K · filed 2024-03-07
2022-09-30-$10.39M
10-Q · filed 2023-11-09
-$19.55M
derived: sum of 2 quarters · filed 2023-11-09
-$27.85M
10-Q · filed 2023-11-09
-$39.16M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$9.16M
10-Q · filed 2023-08-10
-$17.46M
10-Q · filed 2023-08-10
-$28.77M
derived: sum of 3 quarters · filed 2023-08-10
-$39.32M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$8.30M
10-Q · filed 2023-05-15
-$19.61M
derived: sum of 2 quarters · filed 2023-05-15
-$30.16M
derived: sum of 3 quarters · filed 2023-05-15
-$41.10M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$11.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$21.86M
derived: sum of 2 quarters · filed 2023-03-30
-$32.80M
derived: sum of 3 quarters · filed 2023-03-30
-$43.01M
10-K · filed 2023-03-30
2021-09-30-$10.55M
10-Q · filed 2022-11-10
-$21.49M
derived: sum of 2 quarters · filed 2022-11-10
-$31.70M
10-Q · filed 2022-11-10
-$45.45M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$10.94M
10-Q · filed 2022-08-11
-$21.16M
10-Q · filed 2022-08-11
-$34.90M
derived: sum of 3 quarters · filed 2022-08-11
-$45.96M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$10.22M
10-Q · filed 2022-05-11
-$23.96M
derived: sum of 2 quarters · filed 2022-05-11
-$35.02M
derived: sum of 3 quarters · filed 2022-05-11
-$44.41M
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31-$13.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
-$24.80M
derived: sum of 2 quarters · filed 2022-03-30
-$34.19M
derived: sum of 3 quarters · filed 2022-03-30
-$49.62M
10-K · filed 2022-03-30
2020-09-30-$11.06M
10-Q · filed 2021-11-12
-$20.45M
derived: sum of 2 quarters · filed 2021-11-12
-$35.87M
10-Q · filed 2021-11-12
-$67.59M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$9.39M
10-Q · filed 2021-08-12
-$24.81M
10-Q · filed 2021-08-12
-$56.53M
derived: sum of 3 quarters · filed 2021-08-12
-$68.93M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$15.42M
10-Q · filed 2021-05-13
-$47.14M
derived: sum of 2 quarters · filed 2021-05-13
-$59.54M
derived: sum of 3 quarters · filed 2021-05-13
-$81.48M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$31.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10
-$44.12M
derived: sum of 2 quarters · filed 2021-03-10
-$66.06M
derived: sum of 3 quarters · filed 2021-03-10
-$78.17M
10-K · filed 2021-03-10
2019-09-30-$12.40M
10-Q · filed 2020-11-05
-$34.34M
derived: sum of 2 quarters · filed 2020-11-05
-$46.45M
10-Q · filed 2020-11-05
-$56.97M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$21.94M
10-Q · filed 2020-08-06
-$34.05M
10-Q · filed 2020-08-06
-$44.56M
derived: sum of 3 quarters · filed 2020-08-06
-$57.13M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$12.11M
10-Q · filed 2020-05-07
-$22.63M
derived: sum of 2 quarters · filed 2020-05-07
-$35.19M
derived: sum of 3 quarters · filed 2020-05-07
-$46.78M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$10.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$23.07M
derived: sum of 2 quarters · filed 2020-03-12
-$34.67M
derived: sum of 3 quarters · filed 2020-03-12
-$61.52M
10-K · filed 2020-03-12
2018-09-30-$12.56M
10-Q · filed 2019-11-07
-$24.15M
derived: sum of 2 quarters · filed 2019-11-07
-$51.00M
10-Q · filed 2019-11-07
-$57.51M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30-$11.59M
10-Q · filed 2019-08-08
-$38.44M
10-Q · filed 2019-08-08
-$44.95M
derived: sum of 3 quarters · filed 2019-08-08
-$51.76M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31-$26.85M
10-Q · filed 2019-05-09
-$33.35M
derived: sum of 2 quarters · filed 2019-05-09
-$40.17M
derived: sum of 3 quarters · filed 2019-05-09
-$52.63M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31-$6.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
-$13.32M
derived: sum of 2 quarters · filed 2019-03-13
-$25.78M
derived: sum of 3 quarters · filed 2019-03-13
-$30.78M
10-K · filed 2019-03-13
2017-09-30-$6.82M
10-Q · filed 2018-11-07
-$19.28M
derived: sum of 2 quarters · filed 2018-11-07
-$24.27M
10-Q · filed 2018-11-07
-$30.31M
derived: sum of 4 quarters · filed 2018-11-07
2017-06-30-$12.46M
10-Q · filed 2018-08-09
-$17.46M
10-Q · filed 2018-08-09
-$23.50M
derived: sum of 3 quarters · filed 2018-08-09
-$26.77M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31-$5.00M
10-Q · filed 2018-05-09
-$11.03M
derived: sum of 2 quarters · filed 2018-05-09
-$14.30M
derived: sum of 3 quarters · filed 2018-05-09
-$16.36M
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31-$6.04M
10-K · filed 2017-03-06
-$9.31M
derived: sum of 2 quarters · filed 2017-11-08
-$11.36M
derived: sum of 3 quarters · filed 2017-11-08
-$11.02M
10-K · filed 2018-03-14
2016-09-30-$3.27M
10-Q · filed 2017-11-08
-$8.15M
10-K · filed 2017-03-06
-$5.32M
derived: sum of 2 quarters · filed 2017-11-08
-$7.03M
10-Q · filed 2017-11-08
-$26.69M
derived: sum of 4 quarters · filed 2017-11-08
2016-06-30-$2.05M
10-Q · filed 2017-08-09
-$10.71M
10-K · filed 2017-03-06
-$3.75M
10-Q · filed 2017-08-09
-$23.42M
derived: sum of 3 quarters · filed 2017-08-09
-$33.33M
derived: sum of 4 quarters · filed 2017-08-09
2016-03-31-$11.21M
10-K · filed 2017-03-06
-$21.37M
derived: sum of 2 quarters · filed 2017-03-06
-$31.28M
derived: sum of 3 quarters · filed 2017-03-06
-$41.43M
derived: sum of 4 quarters · filed 2017-03-06
2015-12-31-$10.16M
10-K · filed 2017-03-06
-$20.07M
derived: sum of 2 quarters · filed 2017-03-06
-$30.23M
derived: sum of 3 quarters · filed 2017-03-06
-$9.18M
10-K · filed 2018-03-14
2015-09-30-$9.91M
10-K · filed 2017-03-06
-$20.06M
derived: sum of 2 quarters · filed 2017-03-06
-$29.68M
derived: sum of 3 quarters · filed 2017-03-06
-$36.99M
derived: sum of 4 quarters · filed 2017-03-06
2015-06-30-$10.15M
10-K · filed 2017-03-06
-$19.77M
derived: sum of 2 quarters · filed 2017-03-06
-$27.08M
derived: sum of 3 quarters · filed 2017-03-06
-$34.95M
derived: sum of 4 quarters · filed 2017-03-06
2015-03-31-$9.62M
10-K · filed 2017-03-06
-$16.93M
derived: sum of 2 quarters · filed 2017-03-06
-$24.80M
derived: sum of 3 quarters · filed 2017-03-06
-$31.95M
derived: sum of 4 quarters · filed 2017-03-06
2014-12-31-$7.31M
10-K · filed 2017-03-06
-$15.18M
derived: sum of 2 quarters · filed 2017-03-06
-$22.33M
derived: sum of 3 quarters · filed 2017-03-06
-$28.70M
derived: sum of 4 quarters · filed 2017-03-06
2014-09-30-$7.87M
10-K · filed 2017-03-06
-$15.02M
derived: sum of 2 quarters · filed 2017-03-06
-$21.39M
derived: sum of 3 quarters · filed 2017-03-06
-$27.09M
derived: sum of 4 quarters · filed 2017-03-06
2014-06-30-$7.15M
10-K · filed 2017-03-06
-$13.52M
derived: sum of 2 quarters · filed 2017-03-06
-$19.23M
derived: sum of 3 quarters · filed 2017-03-06
-$24.48M
derived: sum of 4 quarters · filed 2017-03-06
2014-03-31-$6.37M
10-K · filed 2017-03-06
-$6.37M
10-Q · filed 2014-05-05
-$12.08M
derived: sum of 2 quarters · filed 2017-03-06
-$17.33M
derived: sum of 3 quarters · filed 2017-03-06
-$22.27M
derived: sum of 4 quarters · filed 2017-03-06
-$226.16M
10-Q · filed 2014-05-05
2013-12-31-$5.71M
10-K · filed 2015-03-24
-$5.70M
10-K · filed 2014-03-26
-$10.96M
derived: sum of 2 quarters · filed 2015-03-24
-$15.90M
derived: sum of 3 quarters · filed 2015-03-24
-$21.48M
10-K · filed 2014-03-26
-$219.79M
10-K · filed 2014-03-26
2013-09-30-$5.25M
10-K · filed 2015-03-24
-$5.25M
10-Q · filed 2013-11-04
-$10.20M
derived: sum of 2 quarters · filed 2015-03-24
-$15.78M
10-Q · filed 2013-11-04
-$19.77M
derived: sum of 4 quarters · filed 2015-03-24
-$214.08M
10-Q · filed 2013-11-04
2013-06-30-$4.94M
10-K · filed 2015-03-24
-$4.94M
10-Q · filed 2013-08-05
-$10.52M
10-Q · filed 2013-08-05
-$14.52M
derived: sum of 3 quarters · filed 2015-03-24
-$17.72M
derived: sum of 4 quarters · filed 2015-03-24
-$208.83M
10-Q · filed 2013-08-05
2013-03-31-$5.58M
10-K · filed 2015-03-24
-$5.58M
10-Q · filed 2013-05-15
-$9.58M
derived: sum of 2 quarters · filed 2015-03-24
-$12.78M
derived: sum of 3 quarters · filed 2015-03-24
-$16.99M
derived: sum of 4 quarters · filed 2015-03-24
-$203.89M
10-Q · filed 2013-05-15
2012-12-31-$4.00M
10-K · filed 2014-03-26
-$7.20M
derived: sum of 2 quarters · filed 2014-03-26
-$11.41M
derived: sum of 3 quarters · filed 2014-03-26
-$15.56M
10-K · filed 2014-03-26
-$198.31M
10-K · filed 2013-03-19
2012-09-30-$3.20M
10-K · filed 2014-03-26
-$7.41M
derived: sum of 2 quarters · filed 2014-03-26
-$11.56M
10-Q · filed 2013-11-04
-$13.93M
derived: sum of 4 quarters · filed 2014-03-26
-$194.31M
10-Q · filed 2012-11-05
2012-06-30-$4.21M
10-K · filed 2014-03-26
-$8.36M
10-Q · filed 2013-08-05
-$10.74M
derived: sum of 3 quarters · filed 2014-03-26
-$14.27M
derived: sum of 4 quarters · filed 2014-03-26
-$191.11M
10-Q · filed 2012-08-06
2012-03-31-$4.15M
10-K · filed 2014-03-26
-$6.52M
derived: sum of 2 quarters · filed 2014-03-26
-$10.06M
derived: sum of 3 quarters · filed 2014-03-26
-$14.46M
derived: sum of 4 quarters · filed 2014-03-26
-$186.90M
10-Q · filed 2012-05-07
2011-12-31-$2.37M
10-K · filed 2013-03-19
-$5.91M
derived: sum of 2 quarters · filed 2013-03-19
-$10.30M
derived: sum of 3 quarters · filed 2013-03-19
-$13.26M
10-K · filed 2013-03-19
-$182.75M
10-K · filed 2012-03-08
2011-09-30-$3.54M
10-K · filed 2013-03-19
-$7.93M
derived: sum of 2 quarters · filed 2013-03-19
-$10.89M
10-Q · filed 2012-11-05
-$13.17M
derived: sum of 4 quarters · filed 2013-03-19
-$180.37M
10-Q · filed 2011-11-08
2011-06-30-$4.39M
10-K · filed 2013-03-19
-$7.35M
10-Q · filed 2012-08-06
-$9.63M
derived: sum of 3 quarters · filed 2013-03-19
-$11.48M
derived: sum of 4 quarters · filed 2013-03-19
-$176.83M
10-Q · filed 2011-08-08
2011-03-31-$2.96M
10-K · filed 2013-03-19
-$5.24M
derived: sum of 2 quarters · filed 2013-03-19
-$7.08M
derived: sum of 3 quarters · filed 2013-03-19
-$12.13M
derived: sum of 4 quarters · filed 2013-03-19
2010-12-31-$2.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-08
-$4.13M
derived: sum of 2 quarters · filed 2012-03-08
-$9.17M
derived: sum of 3 quarters · filed 2012-03-08
-$14.09M
10-K · filed 2012-03-08
2010-09-30-$1.84M
10-Q · filed 2011-11-08
-$6.89M
derived: sum of 2 quarters · filed 2011-11-08
-$11.81M
10-Q · filed 2011-11-08
2010-06-30-$5.04M
10-Q · filed 2011-08-08
-$9.96M
10-Q · filed 2011-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Seaport Therapeutics, Inc. (SPTX)United States$1.131B